ITRI-90
ITRI-90 is an orally effective androgen receptor (AR) PROTAC degrader. ITRI-90 effectively degrades full-length AR (AR-FL) and its splice variant AR-V7 proteins via the ubiquitin-proteasome system, thereby inhibiting AR transcriptional activity and the expression of its target genes, and further inducing tumor cell apoptosis. ITRI-90 can be used in research related to castration-resistant prostate cancer and Enzalutamide (HY-70002)-resistant prostate cancer.
(Pink: Androgen Receptor ligand (HY-171809); Blue: VHL ligand (HY-125845A); Black: linker (HY-169966)).
For research use only. We do not sell to patients.
- CAS No.: 2798907-16-9
- Formula: C45H56F3N9O6S
- Molecular Weight:908.04
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All PROTACs Isoforms
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| LNCaP | DC50 |
2.12 μM
|
Degradation of AR-FL protein in human LNCaP prostate cancer cells after 24 hours of treatment, analyzed via western blotting using an AR N-terminal antibody.
Degradation of AR-FL protein in human LNCaP prostate cancer cells after 24 hours of treatment, analyzed via western blotting using an AR N-terminal antibody.
|
36893587 |
| CWR22R | DC50 |
5.73 μM
|
Degradation of AR-FL protein in human CWR22Rv1 prostate cancer cells after 24 hours of treatment, analyzed via western blotting using an AR N-terminal antibody.
Degradation of AR-FL protein in human CWR22Rv1 prostate cancer cells after 24 hours of treatment, analyzed via western blotting using an AR N-terminal antibody.
|
36893587 |
| VCaP | DC50 |
8.67 μM
|
Degradation of AR-FL protein in human VCaP prostate cancer cells after 24 hours of treatment, analyzed via western blotting using an AR N-terminal antibody.
Degradation of AR-FL protein in human VCaP prostate cancer cells after 24 hours of treatment, analyzed via western blotting using an AR N-terminal antibody.
|
36893587 |
| CWR22R | DC50 |
4.72 μM
|
Degradation of AR-V7 protein in human CWR22Rv1 prostate cancer cells after 24 hours of treatment, analyzed via western blotting using an AR-V7-specific antibody.
Degradation of AR-V7 protein in human CWR22Rv1 prostate cancer cells after 24 hours of treatment, analyzed via western blotting using an AR-V7-specific antibody.
|
36893587 |
| VCaP | DC50 |
0.29 μM
|
Degradation of AR-V7 protein in human VCaP prostate cancer cells after 24 hours of treatment, analyzed via western blotting using an AR-V7-specific antibody.
Degradation of AR-V7 protein in human VCaP prostate cancer cells after 24 hours of treatment, analyzed via western blotting using an AR-V7-specific antibody.
|
36893587 |
| LNCaP | IC50 |
6.587 μM
|
Inhibition of cell viability in human LNCaP prostate cancer cells after 7 days of treatment, measured via alamarBlue assay.
Inhibition of cell viability in human LNCaP prostate cancer cells after 7 days of treatment, measured via alamarBlue assay.
|
36893587 |
| CWR22R | IC50 |
4.134 μM
|
Inhibition of cell viability in human CWR22Rv1 prostate cancer cells after 7 days of treatment, measured via alamarBlue assay.
Inhibition of cell viability in human CWR22Rv1 prostate cancer cells after 7 days of treatment, measured via alamarBlue assay.
|
36893587 |
| VCaP | IC50 |
5.454 μM
|
Inhibition of cell viability in human VCaP prostate cancer cells after 7 days of treatment, measured via alamarBlue assay.
Inhibition of cell viability in human VCaP prostate cancer cells after 7 days of treatment, measured via alamarBlue assay.
|
36893587 |
In Vitro
ITRI-90 (0.01-20 μM; 24 h) degrades full-length AR and truncated AR variant (AR-V) proteins in LNCaP, CWR22Rv1 and VCaP cells, with DC50 values ranging from 2.12 to 8.67 μM for full-length AR degradation and from 0.29 to 4.72 μM for AR-V7 degradation[1].
ITRI-90 (10 μM; eluted after 24 h of treatment and observed at different time points) induces sustained degradation of AR protein in LNCaP, CWR22Rv1 and VCaP cells, and this effect persists for an extended period after drug withdrawal[1].
ITRI-90 (0.5-5 μM; 16-24 h) inhibits DHT-induced KLK3 promoter activity and downregulates the mRNA expression of AR and AR-V7 target genes in LNCaP and CWR22Rv1 cells[1].
ITRI-90 (5-10 μM; 24 h-8 days) reverses the Enzalutamide-induced upregulation of AR and AR-V expression and significantly inhibits the proliferation of drug-resistant cells in Enzalutamide (HY-70002)-acquired resistant C4-2B/EnzR cells and VCaP cells treated with short-term Enzalutamide[1].
ITRI-90 (0.01-100 μM; 24 h-7 days) inhibits cell viability, activates Caspase 3/7, and induces apoptosis in LNCaP, CWR22Rv1, and VCaP cells, while it does not cause AR degradation or exhibit significant cytotoxicity in normal prostate epithelial PNT2 cells and AR-negative PC3 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:LNCaP, CWR22Rv1
-
Concentration:0.1, 1 μM
-
Incubation Time:24 h
-
Result:Reduced the transcriptional levels of AR and specific AR-V7 target genes (such as KLK3, TMPRSS2, UBE2C, CCNA2, etc.).
-
Cell Line:LNCaP, CWR22Rv1, VCaP
-
Concentration:0.01, 0.03, 0.1, 0.3, 1, 3, 10, 20 μM
-
Incubation Time:24 h
-
Result:Dose-dependently degraded full-length AR and AR-V(ΔLBD).
-
Cell Line:LNCaP, CWR22Rv1, VCaP
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Rapidly induced Caspase 3/7 activity, triggering apoptosis in cancer cells.
Parmacokinetics
In Vivo
ITRI-90 (10 mg/kg; i.p.; twice daily; 12 days) significantly inhibits tumor growth without obvious toxic effects in a SCID mouse model bearing subcutaneous xenografts of CWR22Rv1 cells[1].
ITRI-90 (100 mg/kg; p.o.; twice daily; 21 days) exhibits potent antitumor activity and intratumoral AR degradation in a subcutaneous xenograft SCID mouse model implanted with CWR22Rv1 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C.B-17 SCID (male, 4-6 weeks of age, subcutaneous implantation of CWR22Rv1 cells)[1]
-
Dosage:10 mg/kg (TGI day 12); 100 mg/kg (TGI day 21)
-
Administration:i.p.; twice daily; 12 days; p.o.; twice daily; 21 days
-
Result:Achieved an average tumor growth inhibition (TGI) of 76.6% on day 12.
Reduced levels of full-length AR (AR-FL) and AR-V7 protein in tumor samples.
Achieved an average TGI of 71.7% on day 21.
Reduced levels of AR-FL and AR-V protein in tumor samples.
Maintained stable animal body weight with no obvious toxicity observed.
-
Animal Model:C.B-17 SCID (male, subcutaneous implantation of PC3 cells)[1]
-
Dosage:100 mg/kg
-
Administration:p.o.; twice daily; 14 days
-
Result:Showed no antitumor efficacy in this AR-negative prostate cancer model.
Chemical Information
-
CAS No. 2798907-16-9
-
Molecular Weight 908.04
-
Formula C45H56F3N9O6S
-
SMILES
FC(F)(C1=NN=C2N1N=C(N3CCC(C4=CC=C(C=C4)OCCCCOCC(N[C@@H](C(C)(C)C)C(N5[C@@H](C[C@@H](C5)O)C(NCC6=CC=C(C7=C(N=CS7)C)C=C6)=O)=O)=O)CC3)CC2)F
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Dual Luciferin reporter gene assay
Luciferin reporter gene assay is a reporting system to detect the activity of Firefly Luciferase using luciferin as a substrate, which is often used in the research of miRNA target gene verification and promoter transcriptive activity regulation. Dual luciferase usually refers to Firefly luciferase and Renilla luciferase.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)